Treatment options for hepatocellular carcinoma

Expert Review of Gastroenterology and Hepatology

Volumn 2, Issue 1, 2008, Pages 81-92

  Sandhu, Dalbir S ^a   Tharayil, Vivek S ^a   Lai, Jin Ping ^a   Roberts, Lewis R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Targeted therapy

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ALPHA INTERFERON; ANTIESTROGEN; ANTIVIRUS AGENT; BEVACIZUMAB; CISPLATIN; CONTRAST MEDIUM; CYTOTOXIC AGENT; DOXORUBICIN; ERLOTINIB; FLUOROURACIL; HISTONE DEACETYLASE INHIBITOR; IMMUNOMODULATING AGENT; INSULIN RECEPTOR SUBSTRATE 1; MITOGEN ACTIVATED PROTEIN KINASE; NUCLEOSIDE ANALOG; OCTREOTIDE; ONCOLYTIC VIRUS; PI 88; PLACEBO; PROTEOHEPARAN SULFATE; SMALL INTERFERING RNA; SOMATOMEDIN; SORAFENIB; SUNITINIB; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN RECEPTOR; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; CANCER GENE THERAPY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SIZE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL CYCLE REGULATION; CHEMOEMBOLIZATION; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; EARLY DIAGNOSIS; ECHOGRAPHY; HEMOPERITONEUM; HEPATITIS; HEPATITIS C; HUMAN; HYPERSENSITIVITY REACTION; INOPERABLE CANCER; INTERMETHOD COMPARISON; KIDNEY DISEASE; LIVER ABSCESS; LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PLEURA EFFUSION; PREVALENCE; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN TARGETING; RADIOFREQUENCY ABLATION; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIGNAL TRANSDUCTION; SURVIVAL RATE;

CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS;

EID: 49149128398     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/17474124.2.1.81     Document Type: Review

References (72)

1. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2(9), 533-543 (2001).
2. Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 351(9097), 214-215 (1998).
3. El-Serag HB, Davila JA, Petersen NJ, McGlynn KA. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann. Intern. Med. 139(10), 817-823 (2003).
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745-750 (1999).
5. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132(7), 2557-2576 (2007).
6. Taylor-Robinson SD, Foster GR, Arora S, Hargreaves S, Thomas HC. Increase in primary liver cancer in the UK, 1979-94. Lancet 350(9085), 1142-1143 (1997).
7. Kew MC, Popper H. Relationship between hepatocellular carcinoma and cirrhosis. Semin. Liver Dis. 4(2), 136-146 (1984).
8. Llovet JM, Bustamante J, Castells A et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology 29(1), 62-67 (1999).
9. Sangro B, Bilbao I, Herrero I et al. Partial splenic embolization for the treatment of hypersplenism in cirrhosis. Hepatology 18(2), 309-314 (1993).
10. Di Bisceglie AM. Epidemiology and clinical presentation of hepatocellular carcinoma. J. Vasc. Interv. Radiol. 13(9 Pt 2), S169-S171 (2002).
11. Llovet JM, Beaugrand M. Hepatocellular carcinoma: present status and future prospects. J. Hepatol. 38(Suppl. 1), S136-S149 (2003).
12. Kew MC, Yu MC, Kedda MA et al. The relative roles of hepatitis B and C viruses in the etiology of hepatocellular carcinoma in southern African blacks. Gastroenterology 112(1), 184-187 (1997).
13. Di Bisceglie AM. Hepatitis C and hepatocellular carcinoma. Hepatology 26(3 Suppl. 1), S34-S38 (1997).
14. Lin SM, Yu ML, Lee CM et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J. Hepatol. 46(1), 45-52 (2007).
15. Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 295(1), 65-73 (2006).
16. Van Vlierberghe H, Borbath I, Delwaide J et al. BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol. Belg. 67(1), 14-25 (2004).
17. Li D, Mallory T, Satomura S. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin. Chim. Acta 313(1-2), 15-19 (2001).
18. Leerapun A, Suravarapu SV, Bida JP et al. The utility of Lens culinaris agglutinin-reactive α-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin. Gastroenterol. Hepatol. 5(3), 394-402 (2007).
19. Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 27(1), 273-278 (1998).
20. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology 42(5), 1208-1236 (2005).
21. Alberts SR, Gores GJ, Kim GP et al. Treatment options for hepatobiliary and pancreatic cancer. Mayo Clin. Proc. 82(5), 628-637 (2007).
22. OPTN/UNOS Liver and Intestinal Organ Transplantation Committee Meeting. Modifications to the policy 3.6.4.4 (Liver transplant candidates with hepatocellular carcinoma) (2004).
23. Blum HE. Treatment of hepatocellular carcinoma. Best Pract. Res. Clin. Gastroenterol. 19(1), 129-145 (2005).
24. Llover JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30(6), 1434-1440 (1999).
25. Cucchetti A, Ercolani G, Vivarelli M et al. Impact of model for end-stage liver disease (MELD) score on prognosis after hepatectomy for hepatocellular carcinoma on cirrhosis. Liver Transpl. 12(6), 966-971 (2006).
26. Teh S H, Christein J, Donohue J et al. Hepatic resection of hepatocellular carcinoma in patients with cirrhosis: model of end-stage liver disease (MELD) score predicts perioperative mortality. J. Gastrointest. Surg. 9(9), 1207-1215 (2005).
27. Mazzaferro V, Regalia E, Doci R et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med., 334(11), 693-699 (1996).
28. Bharat A, Brown DB, Crippin JS et al. Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J. Am. Coll. Surg. 203(4), 411-420 (2006).
29. Aloia TA, Adam R, Samuel D, Azoulay D, Castaing D. A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation. J. Gastrointest. Surg. 11(10), 1328-1332 (2007).
30. Livraghi T, Giorgio A, Marin G et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaricous ethanol injection. Radiology 197(1), 101-108 (1995).
31. Lencioni R, Pinto F, Armillotta N et al. Long-term results of percutaneous ethanol injection therapy for hepatocellular carcinoma in cirrhosis: a European experience. Eur. Radiol. 7(4), 514-519 (1997).
32. Shiina S, Teratani T, Obi S et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129(1), 122-130 (2005).
33. Millonig G, Graziadei IW, Freund MC et al. Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma. Liver Transpl. 13(2), 272-279 (2007).
34. Llovet JM, Real MI, Montana X et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319), 1734-1739 (2002).
35. Lo CM, Ngan H, Tso WK et al. Randomized controlled trial of transarterial lipiodol chemoembolization for untesectable hepatocellular carcinoma. Hepatology 35 (5), 1164-1171 (2002).
36. Llovet JM, Bruix J. Unresectable hepatocellular carcinoma: meta-analysis of arterial embolization. Radiology 230 (1), 300-301 (2004).
37. Gulec SA, Fong Y. Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Arch. Surg. 142(7), 675-682 (2007).
38. Sato K, Lewandowski RJ, Bui JT et al. Treatment of unresectable primary and metastatic liver cancer with yttrium-90 microspheres (TheraSphere®): assessment of hepatic arterial embolization. Cardiovasc. Intervent. Radiol. (2006).
39. Kulik LM, Atassi B, van Holsbeeck L et al. Yttrium-90 microspheres (TheraSphere®) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J. Surg. Oncol. 94(7), 572-586 (2006).
40. Johnson PJ, Williams P, Thomas H, Sherlock S, Murray-Lyon IM. Induction of remission in hepatocellular carcinoma with doxorubicin. Lancet 1(8072), 1006-1009 (1978).
41. Lai CL, Wu PC, Chan GC, Lok AS, Lin HJ. Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62(3), 479-483 (1988).
42. Leung TW, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin. Oncol. 28(5), 514-520 (2001).
43. Nerenstone SP, Ihde DC, Friedman MA. Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev. 15(1), 1-31 (1988).
44. Leung TW, Tang AM, Zee B et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-α, doxorubicin and 5-fluorouracil chemotherapy. Cancer 94(2), 421-427 (2002).
45. Castells A, Bruix J, Bru C et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 109(3), 917-922 (1995).
46. Chow P, Soo K. Hormonal therapy in hepatocellular carcinoma. The current scientific and clinical evidence. Asian J. Surg. 23, 56-63 (2000).
47. Kouroumalis E, Skordilis P, Thermos K et al. Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 42(3), 442-447 (1998).
48. Becker G, Allgaier HP, Olschewski M, Zahringer A, Blum HE. Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology 45(1), 9-15 (2007).
49. Slijkhuis WA, Stadheim L, Hassoun ZM et al. Octreotide therapy for advanced hepatocellular carcinoma. J. Clin. Gastroenterol. 39(4), 333-338 (2005).
50. Yuen MF, Poon RT, Lai CL et al. A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 36(3), 687-691 (2002).
51. Hui KM. Current approaches in the transcriptional-guided gene therapy of human hepatocellular carcinoma. Curr. Opin. Mol. Ther. 9(4), 378-384 (2007).
52. Ruiz J, Mazzolini G, Sangro B, Qian C, Prieto J. Gene therapy of hepatocellular carcinoma. Dig. Dis 19(4), 324-332 (2001).
53. Blechacz B, Splinter PL, Greiner S et al. Engineered measles virus as a novel oncolytic viral therapy system for hepatocellular carcinoma. Hepatology 44(6), 1465-1477 (2006).
54. Butterfield LH. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology 127(5 Suppl. 1), S232-S241 (2004).
55. Palmer DH, Hussain SA, Johnson PJ. Gene- and immunotherapy for hepatocellular carcinoma. Expert Opin. Biol. Ther. 5(4), 507-523 (2005).
56. Butterfield LH. Recent advances in immunotherapy for hepatocellular cancer. Swiss Med. Wkly 137(5-6), 83-90 (2007).
57. Giannelli G, Napoli N, Antonaci S. Tyrosine kinase inhibitors: a potential approach to the treatment of hepatocellular carcinoma. Curr. Pharm. Des. 13(32), 3301-3304 (2007).
58. Tommasi S, Pinto R, Pilato B, Paradiso A. Molecular pathways and related target therapies in liver carcinoma. Curr. Pharm. Des. 13(32), 3279-3287 (2007).
59. Teufel A, Staib F, Kanzler S et al. Genetics of hepatocellular carcinoma. World J. Gastroenterol. 13(16), 2271-2282 (2007).
60. Branda M, Wands JR. Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology 43(5), 891-902 (2006).
61. Roberts LR, Gores GJ. Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin. Liver Dis. 25(2), 212-225 (2005).
62. Liu L, Cao Y, Chen C et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res. 66(24), 11851-11858 (2006).
63. Wilhelm S, Carter C, Lynch M et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat. Rev. Drug Discov. 5 (10), 835-844 (2006).
64. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J. Clin. Oncol. 24(26), 4293-4300 (2006).
65. Llovet J, Ricci S, Mazzaferro V et al. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(18), 532 (2007).
66. Abou-Alfa G, Johnson P, Knox J et al. Preliminary results from a Phase II, randomized, double-blind study of sorafenib plus doxorubicin versus placebo plus doxorubicin in patients with advanced hepatocellular carcinoma. Proceedings of the 2007 meeting of the European Cancer Organization. Eur. J. Cancer 5 (Suppl.) 259 (2001) (Abstract 3500).
67. Faivre S, Raymond E, Douillard J et al. Phase II trial investigating the efficacy and safety of sunitinib in patients with unresectable hepatocellular carcinoma (HCC). Eur. J. Cancer 5 (4 Suppl.) 270 (2007) (Abstract 3535).
68. Thomas M, Chadha R, Iwasaki M, Glover K, Abbruzzese J. The combination of bevacizumab (B) and erlotinib (E) shows significant biological activity in patients with advanced hepatocellular carcinoma (HCC). 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(18 Suppl.), 4567 (2007).
69. Stommel J, Kimmelman A, Ying H et al. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318 (5848), 287-290 (2007).
70. Lai JP, Chien JR, Moser DR et al. hSulf1 Sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparin-binding growth factor signaling. Gastroenterology 126(1), 231-248 (2004).
71. Lai JP, Yu C, Moser CD et al. SULF1 inhibits tumor growth and potentiates the effects of historic deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 130(7), 2130-2144 (2006).
72. Lai JP HT, Moser CD, Aderca I, Lee JS, Thorgeirsson SS, Roberts LR. SULF2 - A novel oncogenic protein in hepatocellular carcinoma. Presented at: International Liver Cancer Association Annual Meeting 2007. Barcelona, Spain, 5-7 October 2007.